Stocks
AbbVie Financial Statements (ABBV) |
||||||||||
| AbbViesmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 21.02.2020 | 19.02.2021 | 18.02.2022 | 17.02.2023 | 20.02.2024 | 03.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 33 266 | 45 804 | 56 197 | 58 054 | 54 318 | 52 848 | |||
| Operating Income, bln rub | 12 983 | 476.0 | 17 924 | 18 117 | 17 425 | 13 678 | ||||
| EBITDA, bln rub | ? | 13 795 | 6 947 | 26 445 | 26 584 | 18 096 | 17 872 | |||
| Net profit, bln rub | ? | 7 882 | 4 616 | 11 542 | 11 836 | 4 863 | 5 350 | |||
| OCF, bln rub | ? | 13 324 | 17 588 | 22 777 | 24 943 | 22 839 | 16 367 | |||
| CAPEX, bln rub | ? | 552.0 | 798.0 | 787.0 | 695.0 | 777.0 | 424.0 | |||
| FCF, bln rub | ? | 12 772 | 16 790 | 21 990 | 24 248 | 22 062 | 15 943 | |||
| Dividend payout, bln rub | 6 366 | 7 716 | 9 261 | 10 043 | 10 539 | 5 253 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 80.8% | 167.2% | 80.2% | 84.9% | 216.7% | 98.2% | ||||
| OPEX, bln rub | 12 459 | 17 856 | 19 865 | 21 826 | 28 113 | 25 985 | ||||
| Cost of production, bln rub | 7 439 | 15 387 | 17 446 | 17 414 | 8 780 | 13 119 | ||||
| R&D, bln rub | 6 407 | 6 557 | 7 084 | 6 510 | 7 032 | 7 266 | ||||
| Interest expenses, bln rub | 1 509 | 2 280 | 2 384 | 2 230 | 1 669 | 1 667 | ||||
| Assets, bln rub | 89 115 | 150 565 | 146 529 | 138 805 | 134 711 | 148 874 | ||||
| Net Assets, bln rub | ? | -8 172 | 13 076 | 15 408 | 17 254 | 10 360 | 10 397 | |||
| Debt, bln rub | 66 728 | 86 056 | 76 684 | 63 271 | 59 385 | 74 001 | ||||
| Cash, bln rub | 39 924 | 8 479 | 9 830 | 9 229 | 12 816 | 12 816 | ||||
| Net debt, bln rub | 26 804 | 77 577 | 66 854 | 54 042 | 46 569 | 61 185 | ||||
| Ordinary share price, rub | 88.5 | 107.2 | 135.4 | 161.6 | 155.0 | 143.5 | ||||
| Number of ordinary shares, mln | 1 481 | 1 667 | 1 770 | 1 771 | 1 768 | 1 778 | ||||
| Market cap, bln rub | 131 128 | 178 619 | 239 658 | 286 211 | 273 987 | 255 096 | ||||
| EV, bln rub | ? | 157 932 | 256 196 | 306 512 | 340 253 | 320 556 | 316 281 | |||
| Book value, bln rub | -42 425 | -102 924 | -92 922 | -82 341 | -77 543 | -85 254 | ||||
| EPS, rub | ? | 5.32 | 2.77 | 6.52 | 6.68 | 2.75 | 3.01 | |||
| FCF/share, rub | 8.62 | 10.1 | 12.4 | 13.7 | 12.5 | 8.97 | ||||
| BV/share, rub | -28.6 | -61.7 | -52.5 | -46.5 | -43.9 | -48.0 | ||||
| EBITDA margin, % | ? | 41.5% | 15.2% | 47.1% | 45.8% | 33.3% | 33.8% | |||
| Net margin, % | ? | 23.7% | 10.1% | 20.5% | 20.4% | 8.95% | 10.1% | |||
| FCF yield, % | ? | 9.74% | 9.40% | 9.18% | 8.47% | 8.05% | 6.25% | |||
| ROE, % | ? | -96.5% | 35.3% | 74.9% | 68.6% | 46.9% | 51.5% | |||
| ROA, % | ? | 8.84% | 3.07% | 7.88% | 8.53% | 3.61% | 3.59% | |||
| P/E | ? | 16.6 | 38.7 | 20.8 | 24.2 | 56.3 | 47.7 | |||
| P/FCF | 10.3 | 10.6 | 10.9 | 11.8 | 12.4 | 16.0 | ||||
| P/S | ? | 3.94 | 3.90 | 4.26 | 4.93 | 5.04 | 4.83 | |||
| P/BV | ? | -3.09 | -1.74 | -2.58 | -3.48 | -3.53 | -2.99 | |||
| EV/EBITDA | ? | 11.4 | 36.9 | 11.6 | 12.8 | 17.7 | 17.7 | |||
| Debt/EBITDA | 1.94 | 11.2 | 2.53 | 2.03 | 2.57 | 3.42 | ||||
| R&D/CAPEX, % | 1 161% | 821.7% | 900.1% | 936.7% | 905.0% | 1 714% | ||||
| CAPEX/Revenue, % | 1.66% | 1.74% | 1.40% | 1.20% | 1.43% | 0.80% | ||||
| AbbVie shareholders | ||||||||||
